Global
Pipeline

Progress and introduction
of main products

LQ082: Breakthrough Trispecific VHH-An Innovative Approach for Comprehensive IBD Management
Key Advantages

Multi-Pathway Blockade:

TL1A: Reduces pro-inflammatory signaling

IL-23 p19: Lowers Th17 cell activation and IL-17 production

α4β7: Limits lymphocyte migration to the gut

Synergistic Effect: Combined inhibition offers broader anti-inflammatory benefits

Optimized Pharmacokinetics: Extended half-life enables less frequent dosing

Enhanced Safety: Advanced design minimizes immune complex formation, low pre-existing antibodies and ADA

Good Druggability: High yeild and high concentration feasibility

Mechanism of Action

TL1A/DR3 Inhibition: Reduces IFNγ release and dampens inflammation

IL-23/IL-23R Blockade: Inhibits Th17 cell differentiation, lowering IL-17 levels

α4β7 Inhibition: Reduces gut-directed lymphocyte trafficking

These combined actions work together to achieve effective immune modulation in IBD

Indications

IBD– Crohn’s Disease, Ulcerative Colitis

Administration & Pharmacokinetics

Route: Sc. injection.

Pharmacokinetics: Engineered Fc, designed for 2–3× longer half-life than conventional antibodies, allowing for reduced dosing frequency